Stemina Biomarker Discovery Inc. today announced the launch of the largest clinical study of the metabolism of children with autism spectrum disorder (ASD) ever conducted. The Children’s Autism Metabolome Project or “CAMP” study will enroll 1,500 subjects from six sites across the country. CAMP will attempt to confirm that sets of metabolic biomarkers can detect subtypes of ASD.
Earlier Autism Diagnosis Possible for Some Children Based on Metabolic Biomarkers in Blood, New Research Shows
New biomarkers detected in 1,100 subject study accurately identify specific subtypes of ASD related to abnormalities in